East Windsor, NJ—A recent study published in Clinical Dermatology shows that Boswellia cream could potentially aid psoriasis patients, and the results could be far-reaching.

The cream, made by Sabinsa, is derived from Boswellia serrata Roxb extract and standardized for 5% of 95% 3-O-Acetyl-11-Keto Beta Boswellic Acid (AKBBA).

The testing took place in an open label, multi centered phase three clinical trial. 200 psoriatic patients applied the cream three times a day over the course of 12 weeks, and results were gauged by cross-referencing changes with a modified Psoriasis Activity Severity Index (PASI), as well as checking for various biomarkers associated with the disease and charting clinical lesions via photographs. 

Results from the test noted a reduction in overall PASI score, suggesting that there was a anti-inflammatory response from the cream in the patients. The authors of the study believe this could be a particularly valuable find, as many skincare options on the market showed reduced effects in psoriatic patients. U.S. tests of AKBBA are to begin soon, and are intended to have it approved by the FDA as a drug for psoriasis treatment.  In a statement, Muhammad Majeed, PhD., founder of Sabinsa, remarked that his company’s understanding of the ingredient is growing, and that he wants the world to know the positive research and impact it is having on human health. 

Published in WholeFoods Magazine, September 2014